Biggest changeRevenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies , to the accompanying consolidated financial statements. 41 The following table reconciles Net (loss) income to Adjusted EBITDA for the years ended December 31, 2023, 2022, and 2021 (in millions): For the Year Ended December 31, 2023 2022 2021 Net (loss) income $ (79.0) $ (38.3) $ 112.9 Impairment of goodwill 85.8 109.0 — Interest expense 43.0 15.0 0.3 Depreciation and amortization 30.9 33.0 36.9 Unusual or nonrecurring items not typical of ongoing operations (1) 21.2 9.5 11.9 Income tax (benefit) expense (11.4) 12.8 35.1 Stock-based compensation 8.9 9.2 3.6 Net income attributable to noncontrolling interest (1.5) (2.1) (1.8) (Gain) loss on disposal or impairment of assets (0.3) 0.1 (0.8) Stock-based compensation included in overhead allocation — 1.1 2.3 Gain on consolidation of joint venture formerly accounted for under the equity method of accounting — — (3.2) Adjusted EBITDA $ 97.6 $ 149.3 $ 197.2 The following table reconciles Net cash provided by operating activities to Adjusted EBITDA for the years ended December 31, 2023, 2022, and 2021 (in millions): For the Year Ended December 31, 2023 2022 2021 Net cash provided by operating activities $ 48.4 $ 80.1 $ 123.3 Interest expense excluding amortization of debt discounts and fees 40.9 15.0 0.3 Unusual or nonrecurring items not typical of ongoing operations (1) 21.2 9.5 11.9 Change in assets and liabilities, excluding derivative instruments (11.9) 29.2 32.8 Net income attributable to noncontrolling interests in continuing operations (1.5) (2.1) (1.8) Other 0.3 (0.6) 1.6 Current portion of income tax (benefit) expense 0.2 17.1 26.5 Equity in net income of nonconsolidated affiliates — — 0.6 Distributions from nonconsolidated affiliates — — (0.3) Stock-based compensation included in overhead allocation — 1.1 2.3 Adjusted EBITDA $ 97.6 $ 149.3 $ 197.2 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, one-time standalone transition costs, shareholder activism and the strategic review process; in 2022, they include one-time standalone transition costs and costs associated with nonroutine litigation.
Biggest changeRevenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies , to the accompanying consolidated financial statements. 37 Table of Contents The following table reconciles Net loss to Adjusted EBITDA for the years ended December 31, 2024, 2023, and 2022 (in millions): Year Ended December 31, 2024 2023 2022 Net loss $ (154.0) $ (79.0) $ (38.3) Interest expense and amortization of debt discounts and fees 42.9 43.0 15.0 (Benefit from) provision for income taxes (4.0) (11.4) 12.8 Depreciation and amortization 31.5 30.9 33.0 (Gain) loss on disposal or impairment of assets (0.7) (0.3) 0.1 Impairment of goodwill 161.7 85.8 109.0 Stock-based compensation 11.7 8.9 9.2 Stock-based compensation included in overhead allocation — — 1.1 Net income attributable to noncontrolling interests (2.2) (1.5) (2.1) Unusual or nonrecurring items not typical of ongoing operations 13.2 21.2 9.5 Adjusted EBITDA $ 100.1 $ 97.6 $ 149.3 The following table reconciles Net cash provided by operating activities to Adjusted EBITDA for the years ended December 31, 2024, 2023, and 2022 (in millions): Year Ended December 31, 2024 2023 2022 Net cash provided by operating activities $ 51.2 $ 48.4 $ 80.1 Interest expense excluding amortization of debt discounts and fees 41.4 40.9 15.0 Current portion of (benefit from) provision for income taxes 1.7 0.2 17.1 Change in assets and liabilities, excluding derivative instrument (5.2) (11.9) 29.2 Net income attributable to noncontrolling interests (2.2) (1.5) (2.1) Unusual or nonrecurring items that are not typical of ongoing operations 13.2 21.2 9.5 Stock-based compensation included in overhead allocation — — 1.1 Other — 0.3 (0.6) Adjusted EBITDA $ 100.1 $ 97.6 $ 149.3 Unusual or nonrecurring items in the year ended December 31, 2024 include: (i) third-party legal and advisory fees related to shareholder activism; (ii) third-party legal and advisory fees related to the strategic review process that concluded in May 2024; (iii) certain third-party, nonrecurring litigation fees related to a lawsuit in which the Company is a plaintiff, styled Enhabit, Inc. et al v.
For more information on the Separation, see Item 1, “ Business—History .” COVID-19 Pandemic Impact on Our Results of Operations In response to the COVID-19 outbreak and ensuing pandemic (the “pandemic”), Congress and CMS adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care.
For more information on the Separation, see Item 1, “ Business—Our History .” COVID-19 Pandemic Impact on Our Results of Operations In response to the COVID-19 outbreak and ensuing pandemic (the “pandemic”), Congress and CMS adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care.
Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America (“GAAP”), and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for Net (loss) income .
Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America (“GAAP”), and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for Net income (loss).
The projected operating results use management’s best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. Other significant estimates and assumptions include cost-saving synergies and tax benefits that would accrue to a market participant under a fair value 50 methodology.
The projected operating results use management’s best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. Other significant estimates and assumptions include cost-saving synergies and tax benefits that would accrue to a market participant under a fair value methodology.
We expect the United States’ aging population will continue to increase long-term demand for the services we provide, which we believe will help us grow our home health and hospice volumes.
We expect the United States’ aging population will continue to increase long-term demand for our services, which we believe will help us grow our Home Health and Hospice volumes.
We target markets for expansion and growth that 38 allow us to leverage our existing operations to create operating efficiencies through scale and density. We also leverage technology to create operating and supply chain efficiencies throughout our organization.
We target markets for expansion and growth that allow us to leverage our existing operations to create operating efficiencies through scale and density. We also leverage technology to create operating and supply chain efficiencies throughout our organization.
See “— Results of Operations .” For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of total adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”) to ( Loss) i ncome before income taxes and noncontrolling interests , see Note 14, Segment Reporting , to the accompanying consolidated financial statements.
See “— Results of Operations .” For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of total adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”) to Loss before income taxes and noncontrolling interests, see Note 14, Segment Reporting , to the accompanying consolidated financial statements.
Our purchase obligations primarily relate to software licensing and support. Purchase obligations are not recognized in our Consolidated Balance Sheet. For more information, see Note 13, Contingencies and Other Commitments , to the accompanying consolidated financial statements. Our capital expenditures include costs associated with computer hardware and licensing software we utilize to run our business, as well as leasehold improvements.
Our purchase obligations primarily relate to software licensing and support. Purchase obligations are not recognized in our Consolidated Balance Sheets. For more information, see Note 13, Contingencies and Other Commitments , to the accompanying consolidated financial statements. Our capital expenditures include costs associated with computer hardware and licensing software we utilize to run our business, as well as leasehold improvements.
We believe the growing percentage of seniors experiencing chronic conditions will result in higher utilization of home health services in the future as patients require more care to support these conditions. Due to the continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries, we expect the volume of third-party payors to shift and evolve.
We believe the growing percentage of seniors experiencing chronic conditions will result in higher utilization of home health services in the future as patients require more care to support these conditions. Due to the continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries, we expect the volume of third-party payers to shift and evolve.
See Item 1, “ Business ,” and Item 1A, “ Risk Factors ,” and “—S egment Results of Operations ,” in this Annual Report, as well as Note 14, Segment Reporting , to the accompanying consolidated financial statements. We are also impacted by changes in reimbursement rates by other payors, and in particular, Medicare Advantage plans.
See Item 1, “ Business ,” and Item 1A, “ Risk Factors ,” and “—S egment Results of Operations ,” in this Annual Report, as well as Note 14, Segment Reporting , to the accompanying consolidated financial statements. We are also impacted by changes in reimbursement rates by other payers, and in particular, Medicare Advantage plans.
Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third‑party payors, which are often subject to interpretation and review, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material.
Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third‑party payers, which are often subject to interpretation and review, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material.
See Note 1, Summary of Significant Accounting Policies—Net service revenue , to the accompanying consolidated financial statements for a complete discussion of our revenue recognition policies. Our patient accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor.
See Note 1, Summary of Significant Accounting Policies—Net Service Revenue , to the accompanying consolidated financial statements for a complete discussion of our revenue recognition policies. Our patient accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payer.
Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances (principally for patients covered by Medicare, Medicare Advantage, Medicaid, and other third-party payors), potential adjustments that may arise from payment and other reviews, and uncollectible amounts.
Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances (principally for patients covered by Medicare, Medicare Advantage, Medicaid, and other third-party payers), potential adjustments that may arise from payment and other reviews, and uncollectible amounts.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section is designed to provide a reader of our financial statements with a narrative from the perspective of management on our financial condition, results of operations, liquidity, and other factors that may affect our future results.
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section is designed to provide a reader of our financial statements with a narrative from the perspective of management on our financial condition, results of operations, liquidity, and other factors that may affect our future results.
Certain other factors that are considered and could influence the estimated transaction price are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional adjustments are provided to account for these factors.
Certain other factors that are considered and could influence the estimated transaction price are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payer classes, and additional adjustments are provided to account for these factors.
Liquidity and Capital Resources Our principal uses of cash include the funding of working capital requirements, servicing our debt, and funding capital expenditures, including acquisitions. See “— Contractual Obligations ” for more information about our material cash requirements from our contractual obligations at December 31, 2023.
Liquidity and Capital Resources Our principal uses of cash include the funding of working capital requirements, servicing our debt, and funding capital expenditures, including acquisitions. See “— Contractual Obligations ” for more information about our material cash requirements from our contractual obligations at December 31, 2024.
Our collection risks include payment denials by payors as a result of increasing complexities of documentation requirements, pre- and post-payment claim reviews by our respective MACs, and reimbursement claims audits by governmental or other payors and their agents.
Our collection risks include payment denials by payers as a result of increasing complexities of documentation requirements, pre- and post-payment claim reviews by our respective MACs, and reimbursement claims audits by governmental or other payers and their agents.
Information on the concentration of total patient accounts receivable by payor class can be found in Note 1, Summary of Significant Accounting Policies—Accounts Receivable, Net of Allowances , to the accompanying consolidated financial statements.
Information on the concentration of total patient accounts receivable by payer class can be found in Note 1, Summary of Significant Accounting Policies—Accounts Receivable, Net of Allowances , to the accompanying consolidated financial statements.
If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. See Note 1, Summary of Significant Accounting Policies—Net Service Revenue and — Accounts Receivable, Net of Allowances to the accompanying consolidated financial statements.
If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. See Note 1, Summary of Significant Accounting 45 Table of Contents Policies—Net Service Revenue and — Accounts Receivable, Net of Allowances , to the accompanying consolidated financial statements.
As of December 31, 2023 and 2022, the amount of our patient accounts receivable representing denials that were under review or audit in excess of reserves established for such denials was $1.8 million and $2.5 million, respectively, in our home health segment and $2.2 million and $1.6 million, respectively, in our hospice segment.
As of December 31, 2024 and 2023, the amount of our patient accounts receivable representing denials that were under review or audit in excess of reserves established for such denials was $1.2 million and $1.8 million, respectively, in our Home Health segment and $1.5 million and $2.2 million, respectively, in our Hospice segment.
Additionally, we have little or no ability to pass on these increased costs associated with providing service to Medicare Advantage and other third-party payor patients due to contractually negotiated rates. Recruiting and Retaining High-Quality Personnel Recruiting and retaining qualified personnel, including management, for our home health and hospice agencies remains a high priority for us.
Additionally, we have little or no ability to pass on these increased costs associated with providing service to Medicare Advantage and other third-party payer patients due to contractually negotiated rates. Recruiting and Retaining High-Quality Personnel Recruiting and retaining qualified personnel, including management, for our home health agencies and hospice provider locations remains a high priority for us.
While we treat patients of all ages, most of our patients are 65 and older, and, due to the increasingly aging U.S. population, the number of Medicare enrollees is expected to continue to grow approximately 3% per year. More specifically, the average age of our home health patients and hospice patients is approximately 75 and 80, respectively.
While we treat patients of all ages, most of our patients are 65 and older, and, due to the increasingly aging U.S. population, the number of Medicare enrollees is expected to continue to grow approximately 3% per year. More specifically, the average age of our home health patients and hospice patients is approximately 76 and 83, respectively.
(d) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancellable without penalty.
(4) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty.
In addition, increases in healthcare costs are typically higher than inflation and, as such, would impact our costs under employee benefit plans. Managing these costs remains a significant challenge and priority for us. Suppliers may pass along rising costs to us in the form of higher prices.
In addition, increases in labor costs in the healthcare industry are typically higher than inflation 34 Table of Contents and, as such, would impact our costs under employee benefit plans. Managing these costs remains a significant challenge and priority for us. Suppliers may pass along rising costs to us in the form of higher prices.
(c) In addition to our corporate headquarters office space, our home health and hospice segments lease: (1) relatively small office spaces in the localities they serve; and (2) equipment in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note 6, Leases , to the accompanying consolidated financial statements.
(3) In addition to our corporate headquarters office space, our Home Health and Hospice segments lease: (a) relatively small office spaces in the localities they serve; and (b) equipment in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note 6, Leases , to the accompanying consolidated financial statements.
We include the results of operations of the businesses acquired as of the beginning of the acquisition dates. Recent Accounting Pronouncements For information regarding recent accounting pronouncements, see Note 1, Summary of Significant Accounting Policies , to the accompanying consolidated financial statements.
We include the results of operations of the businesses acquired as of the beginning of the acquisition dates. See Note 2, Business Combinations , to the accompanying consolidated financial statements for additional information. Recent Accounting Pronouncements For information regarding recent accounting pronouncements, see Note 1, Summary of Significant Accounting Policies , to the accompanying consolidated financial statements.
As of December 31, 2023, our footprint comprised 255 home health and 110 hospice locations across 34 states. 37 Our operations are principally managed on a services basis and include two operating segments for financial reporting purposes: (1) home health; and (2) hospice.
As of December 31, 2024, our footprint comprised 255 home health and 115 hospice locations across 34 states. Our operations are principally managed on a services basis and include two operating segments for financial reporting purposes: (1) Home Health; and (2) Hospice.
For additional information, see “— Results of Operations ” and “— Segment Results of Operations .” Segment Results of Operations Our segment and consolidated Net service revenue for the years ended December 31, 2023, 2022, and 2021 is provided in the table below.
For additional information, see “— Results of Operations ” and “— Segment Results of Operations .” 38 Table of Contents Segment Results of Operations Our segment and consolidated Net service revenue for the years ended December 31, 2024, 2023, and 2022 is provided in the table below.
The resumption of sequestration negatively impacted our home health and hospice revenues by $10.1 million and $2.4 million, respectively, for the year ended December 31, 2022. The lasting impact of the pandemic remains unknown and difficult to predict.
Sequestration resumed in full on July 1, 2022. The resumption of sequestration negatively impacted our Home Health and Hospice revenues by $10.1 million and $2.4 million, respectively, for the year ended December 31, 2022. The lasting impact of the pandemic remains unknown and difficult to predict.
For a comparison of our results of operations for the years ended December 31, 2022 to 2021, see Item 7, “ Management's Discussion and Analysis of Financial Condition and Results of Operations ,” of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on April 14, 2023.
For a comparison of our results of operations for the years ended December 31, 2023 to 2022, see Item 7, “ Management's Discussion and Analysis of Financial Condition and Results of Operations ,” of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 15, 2024.
For example, in the year ended December 31, 2022, Medicare Advantage patients accounted for 14.2% of our revenue as compared to 19.0% for the year ended December 31, 2023. In addition to organic growth, our strategy includes volume growth through de novo location openings and strategic acquisitions.
For example, in the year ended December 31, 2023, Medicare Advantage patients accounted for 19% of our revenue as compared to 23% for the year ended December 31, 2024. In addition to organic growth, our strategy includes volume growth through de novo location openings and strategic acquisitions.
As of December 31, 2023 2022 (in Millions) Current 0 – 30 Days $ 102.5 $ 109.9 31 – 60 Days 24.2 22.0 61 – 90 Days 12.6 10.2 91 – 120 Days 8.1 4.5 120 + Days 17.3 3.0 Current accounts receivable, net of allowances 164.7 149.6 Noncurrent patient accounts receivable, net of allowances 0.5 0.9 Accounts receivable, net of allowances $ 165.2 $ 150.5 Changes in general economic conditions (such as increased unemployment rates or periods of recession), business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable.
As of December 31, (in millions) 2024 2023 Current 0 – 30 Days $ 92.5 $ 102.5 31 – 60 Days 16.6 24.2 61 – 90 Days 8.9 12.6 91 – 120 Days 6.1 8.1 120 + Days 25.1 17.3 Current accounts receivable, net of allowances 149.2 164.7 Noncurrent patient accounts receivable, net of allowances 0.5 0.5 Accounts receivable, net of allowances $ 149.7 $ 165.2 Changes in general economic conditions (such as increased unemployment rates or periods of recession), business office operations, payer mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable.
Based on the sensitivity analysis performed at September 30, 2023 by reporting unit, it was determined that, assuming all other assumptions and inputs used in the discounted cash flow analysis are held constant, a 50 and 100 basis point increase in the discount rate assumption would result in decreases in the fair value of the home health and hospice reporting units of approximately $35 million and $10 million, respectively.
Based on the sensitivity analysis performed at December 31, 2024 by reporting unit, it was determined that, assuming all other assumptions and inputs used in the discounted cash flow analysis are held constant, a 50 and 100 basis point increase in the discount rate assumption would result in decreases in the fair value of the Home Health and Hospice reporting units, respectively, of approximately $20 million and $15 million, respectively.
As of December 31, 2023, we also had $33.4 million available to us under the Revolving Credit Facility, as discussed below.
As of December 31, 2024, we also had $51.4 million available to us under the Revolving Credit Facility, as discussed below.
For additional information regarding our debt, see Note 8, Long-term Debt , to the accompanying consolidated financial statements and “ —Quantitative and Qualitative Disclosures about Market Risk .” For additional information regarding our interest rate swap, see Note 12, Derivative Instruments , to the accompanying consolidated financial statements. 47 The following table shows the cash flows provided by or used in operating, investing, and financing activities for the years ended December 31, 2023, 2022, and 2021 (in millions): For the Year Ended December 31, 2023 2022 2021 Net cash provided by operating activities $ 48.4 $ 80.1 $ 123.3 Net cash used in investing activities (5.3) (42.3) (119.2) Net cash used in financing activities (40.5) (18.6) (36.1) Increase (decrease) in cash, cash equivalents, and restricted cash $ 2.6 $ 19.2 $ (32.0) Operating activities .
For additional information regarding our debt, see Note 8, Long-Term Debt , to the accompanying consolidated financial statements and “ —Quantitative and Qualitative Disclosures about Market Risk .” The following table shows the cash flows provided by or used in operating, investing, and financing activities for the years ended December 31, 2024, 2023, and 2022 (in millions): Year Ended December 31, 2024 2023 2022 Net cash provided by operating activities $ 51.2 $ 48.4 $ 80.1 Net cash used in investing activities (2.4) (5.3) (42.3) Net cash used in financing activities (48.3) (40.5) (18.6) Increase in cash, cash equivalents, and restricted cash $ 0.5 $ 2.6 $ 19.2 Operating Activities .
The decrease in Net cash provided by operating activities for the year ended December 31, 2023 as compared to the year ended December 31, 2022 resulted primarily from the increase in Net loss , partially offset by changes in working capital. Investing activities .
The increase in Net cash provided by operating activities for the year ended December 31, 2024 as compared to the prior year resulted primarily from changes in working capital, which was partially offset by the increase in Net loss. Investing Activities .
Amounts include interest portion of future minimum finance lease payments. For more information, see Note 6, Leases , to the accompanying consolidated financial statements. (b) Interest on long-term debt was calculated using the rate for the Term Loan A Facility as of December 31, 2023.
Amounts include interest portion of future minimum finance lease payments. For more information, see Note 6, Leases , to the accompanying consolidated financial statements. (2) Interest on long-term debt was calculated using the rate for the credit facilities as of December 31, 2024.
Our primary collection risks relate to the increasing complexities of documentation requirements by payors and claims reviews conducted by MACs or other contractors. 49 The table below shows a summary of our total Accounts receivable, net of allowances as of December 31, 2023 and 2022.
Our primary collection risks relate to the increasing complexities of documentation requirements by payers and claims reviews conducted by Medicare Administrative Contractors (“MACs”) or other contractors. The table below shows a summary of our total Accounts receivable, net of allowances, as of December 31, 2024 and 2023.
As of December 31, 2023 and 2022, we had $27.4 million and $22.9 million, respectively, in Cash and cash equivalents . These amounts exclude $2.4 million and $4.3 million, respectively, in Restricted cash .
As of December 31, 2024 and 2023, we had $28.4 million and $27.4 million, respectively, in Cash and cash equivalents. These amounts exclude $1.9 million and $2.4 million, respectively, in Restricted cash.
We also evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes.
Income Taxes We provide for income taxes using the asset and liability method. We also evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes.
See “— Segment Results of Operations .” Cost of Service, Excluding Depreciation and Amortization Cost of service , excluding depreciation and amortization represents the cost of operating our business, which primarily consists of payroll and related benefits, travel, supplies, including pharmacy for hospice patients, and rental cost for our locations.
See “ —Segment Results of Operations .” Cost of service, excluding depreciation and amortization, represents the cost of operating our business, which primarily consists of payroll and related benefits, travel, supplies, including pharmacy for Hospice patients, and lease costs for our locations. 36 Table of Contents General and Administrative Expenses.
See Item 1, “ Business — Sources of Revenue ,” for a table identifying the sources and relative payor mix of our revenues. Sequestration resumed as of April 1, 2022 and resulted in a 1% payment reduction through June 30, 2022. Thereafter, the full 2% Medicare payment reduction resumed. Additional Medicare payment reductions are also possible under the Statutory PAYGO.
See Item 1, “ Business — Sources of Revenue ,” for a table identifying the sources and relative payer mix of our revenues. Sequestration resumed as of April 1, 2022 and resulted in a 1% payment reduction through June 30, 2022. Thereafter, the full 2% Medicare payment reduction resumed.
Impairment of goodwill for the year ended December 31, 2022 resulted from an impairment charge to reduce the carrying value of our home health reporting unit to its fair value. See Note 7, Goodwill and Other Intangible Assets, Net , to the accompanying consolidated financial statements for additional information.
For the year ended December 31, 2023, Impairment of goodwill resulted from an impairment charge to reduce the carrying value of our Hospice reporting unit to its fair value. See Note 7, Goodwill and Other Intangible Assets, Net , to the accompanying consolidated financial statements for additional information. Interest Expense and Amortization of Debt Discounts and Fees.
Various factors, including competition and increasing regulatory and administrative burdens, impact our ability to maintain and grow our home health and hospice volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages.
Volume The volume of services we provide has a significant impact on our Net service revenue. Various factors, including competition and increasing regulatory and administrative burdens, impact our ability to maintain and grow our Home Health and Hospice volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages.
During the years ended December 31, 2023 and 2022, we made capital expenditures of $3.5 million and $7.1 million, respectively, for property and equipment. These expenditures in 2023 and 2022 were exclusive of $2.8 million and $36.3 million, respectively, in net cash related to our acquisition activity. During 2024, we expect to spend approximately $6 million for maintenance capital expenditures.
During the years ended December 31, 2024 and 2023, we made capital expenditures for property and equipment of $3.8 million and $3.5 million, respectively. These expenditures in 2023 were exclusive of $2.8 million in net cash related to our acquisition activity. There was no acquisition activity in 2024.
We calculate Adjusted EBITDA as Net (loss) income adjusted to exclude (1) income tax (benefit) expense, (2) interest expense and amortization of debt discounts and fees, (3) depreciation and amortization, (4) gains or losses on disposal or impairment of assets or goodwill, (5) stock‑based compensation, (6) net income attributable to noncontrolling interest, (7) unusual or nonrecurring items not typical of ongoing operations, and (8) gain on consolidation of joint venture formerly accounted for under the equity method of accounting.
We calculate Adjusted EBITDA as Net income (loss) adjusted to exclude (1) interest expense and amortization of debt discounts and fees, (2) provision for or benefit from income taxes, (3) depreciation and amortization, (4) gains or losses on disposal or impairment of assets or goodwill, (5) stock‑based compensation, (6) net income attributable to noncontrolling interests, and (7) unusual or nonrecurring items not typical of ongoing operations.
Actual amounts spent will be dependent upon the timing of projects for our business. As of December 31, 2023, we do not have any material off-balance sheet arrangements. 48 Critical Accounting Estimates Our consolidated financial statements are prepared in accordance with GAAP.
During 2025, we expect to spend approximately $5 million for maintenance capital expenditures. Actual amounts spent will be dependent upon the timing of projects for our business. As of December 31, 2024, we do not have any material off-balance sheet arrangements. Critical Accounting Estimates Our consolidated financial statements are prepared in accordance with GAAP.
Assessment of Loss Contingencies We have contingencies that could result in significant losses upon the ultimate resolution of such contingencies. We have provided for losses in situations where we have concluded it is probable a loss has been or will be incurred and the amount of loss is reasonably estimable.
Assessment of Loss Contingencies We provide for losses in situations where we have concluded it is probable a loss has been or will be incurred and the amount of loss is reasonably estimable.
Our evaluation of any required liability for unrecognized tax benefits contains uncertainties because management is required to make assumptions and to apply judgment to estimate the exposures associated with our various filing positions which are periodically audited by tax authorities.
The amount of the valuation allowance may be adjusted in future periods in the event of changes to these factors. Our evaluation of any required liability for unrecognized tax benefits contains uncertainties because management is required to make assumptions and to apply judgment to estimate the exposures associated with our various filing positions which are periodically audited by tax authorities.
The decrease in Net cash used in investing activities for the year ended December 31, 2023 as compared to the year ended December 31, 2022 resulted primarily from three acquisitions in the fourth quarter of 2022. See Note 2, Business Combinations . Financing activities .
The decrease in Net cash used in investing activities for the year ended December 31, 2024 as compared to the prior year resulted primarily from one acquisition in 2023. See Note 2, Business Combinations . Financing Activities .
Segment Adjusted EBITDA is calculated similarly to consolidated Adjusted EBITDA but excludes corporate overhead costs that are not allocated to reportable segments because they are not considered when management evaluates segment performance. See Note 14, Segment Reporting , to the accompanying consolidated financial statements for additional information about Segment Adjusted EBITDA.
Segment Adjusted EBITDA is calculated similarly to consolidated Adjusted EBITDA but excludes corporate overhead costs that are not allocated to reportable segments because they are not considered when management evaluates segment performance.
For discussion of the financial and operational impacts we have experienced as a result of the pandemic, see the sections titled Item 1, “ Business ,” Item 1A, “ Risk Factors ,” “— Results of Operations ,” and “— Segment Results of Operations .” 39 Results of Operations Our consolidated results of operations for the years ended December 31, 2023, 2022, and 2021 were as follows: For the Year Ended December 31, Percentage Change 2023 2022 2021 2023 vs 2022 2022 vs 2021 (in Millions) Net service revenue $ 1,046.3 $ 1,071.1 $ 1,106.6 (2.3) % (3.2) % Cost of service, excluding depreciation and amortization 535.6 525.6 513.9 1.9 % 2.3 % Gross margin, excluding depreciation and amortization 510.7 545.5 592.7 (6.4) % (8.0) % General and administrative expenses 441.6 414.9 412.9 6.4 % 0.5 % Depreciation and amortization 30.9 33.0 36.9 (6.4) % (10.6) % Impairment of goodwill 85.8 109.0 — (21.3) % N/A Operating (loss) income (47.6) (11.4) 142.9 317.5 % (108.0) % Interest expense and amortization of debt discounts and fees 43.0 15.0 0.3 186.7 % 4900.0 % Equity in net income of nonconsolidated affiliates — — (0.6) N/A (100.0) % Other income (0.2) (0.9) (4.8) (77.8) % (81.3) % (Loss) income before income taxes and noncontrolling interests (90.4) (25.5) 148.0 254.5 % (117.2) % Income tax (benefit) expense (11.4) 12.8 35.1 (189.1) % (63.5) % Net (loss) income (79.0) (38.3) 112.9 106.3 % (133.9) % Less: Net income attributable to noncontrolling interests 1.5 2.1 1.8 (28.6) % 16.7 % Net (loss) income attributable to Enhabit, Inc. $ (80.5) $ (40.4) $ 111.1 99.3 % (136.4) % The following table sets forth our consolidated results as a percentage of Net service revenue : For the Year Ended December 31, 2023 2022 2021 Cost of service, excluding depreciation and amortization 51.2 % 49.1 % 46.4 % General and administrative expenses 42.2 % 38.7 % 37.3 % Depreciation and amortization 3.0 % 3.1 % 3.3 % Interest expense 4.1 % 1.4 % — % Net Service Revenue Our Net service revenue decreased for the year ended December 31, 2023 as compared to December 31, 2022 primarily due to the continued shift to more non-episodic patients in home health and the resumption of sequestration.
For discussion of the financial and operational impacts we have experienced as a result of the pandemic, see the sections titled Item 1, “ Business ,” Item 1A, “ Risk Factors ,” “— Results of Operations ,” and “— Segment Results of Operations .” 35 Table of Contents Results of Operations Our consolidated results of operations for the years ended December 31, 2024, 2023, and 2022 were as follows: Year Ended December 31, Percentage Change (in millions, except percentages) 2024 2023 2022 2024 vs 2023 2023 vs 2022 Net service revenue $ 1,034.8 $ 1,046.3 $ 1,071.1 (1.1) % (2.3) % Cost of service, excluding depreciation and amortization 530.8 535.6 525.6 (0.9) % 1.9 % Gross margin, excluding depreciation and amortization 504.0 510.7 545.5 (1.3) % (6.4) % General and administrative expenses 425.9 441.6 414.9 (3.6) % 6.4 % Depreciation and amortization 31.5 30.9 33.0 1.9 % (6.4) % Impairment of goodwill 161.7 85.8 109.0 88.5 % (21.3) % Operating loss (115.1) (47.6) (11.4) 141.8 % 317.5 % Interest expense and amortization of debt discounts and fees 42.9 43.0 15.0 (0.2) % 186.7 % Other income — (0.2) (0.9) (100.0) % (77.8) % Loss before income taxes and noncontrolling interests (158.0) (90.4) (25.5) 74.8 % 254.5 % (Benefit from) provision for income taxes (4.0) (11.4) 12.8 (64.9) % (189.1) % Net loss (154.0) (79.0) (38.3) 94.9 % 106.3 % Less: Net income attributable to noncontrolling interests 2.2 1.5 2.1 46.7 % (28.6) % Net loss attributable to Enhabit, Inc. $ (156.2) $ (80.5) $ (40.4) 94.0 % 99.3 % The following table sets forth our consolidated results as a percentage of Net service revenue: Year Ended December 31, 2024 2023 2022 Cost of service, excluding depreciation and amortization 51.3 % 51.2 % 49.1 % General and administrative expenses 41.2 % 42.2 % 38.7 % Depreciation and amortization 3.0 % 3.0 % 3.1 % Interest expense 4.1 % 4.1 % 1.4 % Net Service Revenue.
Segment Adjusted EBITDA The decrease in Segment Adjusted EBITDA for the year ended December 31, 2023 as compared to the year ended December 31, 2022 resulted primarily from the decrease in Net service revenue as discussed above. 44 Hospice During the years ended December 31, 2023, 2022, and 2021, our hospice segment derived its Net service revenue from the following payor sources: For the Year Ended December 31, 2023 2022 2021 Medicare 97.1 % 98.8 % 97.9 % Managed care 2.5 % 0.7 % 1.5 % Medicaid 0.4 % 0.5 % 0.6 % Total 100.0 % 100.0 % 100.0 % Additional information regarding our hospice segment’s operating results for the years ended December 31, 2023, 2022, and 2021 is as follows: For the Year Ended December 31, Percentage Change 2023 2022 2021 2023 vs. 2022 2022 vs. 2021 (In Millions, Except Percentage Change) Hospice segment revenue $ 196.2 $ 194.0 $ 209.3 1.1 % (7.3) % Cost of service, excluding depreciation and amortization 96.6 90.1 90.4 7.2 % (0.3) % Gross margin, excluding depreciation and amortization 99.6 103.9 118.9 (4.1) % (12.6) % General and administrative expenses 63.4 65.2 62.6 (2.8) % 4.2 % Equity earnings and noncontrolling interests 0.1 0.3 0.1 (66.7) % 200.0 % Hospice Segment Adjusted EBITDA (a) $ 36.1 $ 38.4 $ 56.2 (6.0) % (31.7) % For the Year Ended December 31, Percentage Change 2023 2022 2021 2023 vs. 2022 2022 vs. 2021 (Actual Amounts) Total: Admissions 11,713 11,978 13,113 (2.2)% (8.7)% Patient days 1,256,081 1,284,386 1,372,980 (2.2)% (6.5)% Average daily census 3,441 3,519 3,762 (2.2)% (6.5)% Revenue per patient day $ 156 $ 151 $ 152 3.3% (0.7)% Cost per patient day $ 77 $ 70 $ 66 10.0% 6.1% (a) Segment Adjusted EBITDA is presented in conformity with ASC 280, Segment Reporting , as a measure reported to management for purposes of making decisions on allocating resources and addressing the performance of our segments.
Home Health segment General and administrative expenses decreased 2.2% as compared to the prior year due to cost savings initiatives and lower benefit related expenses, partially offset by annual merit increases in the fourth quarter of 2023 and 2024. 41 Table of Contents Hospice During the years ended December 31, 2024, 2023, and 2022, our Hospice segment derived its Net service revenue from the following payer sources: Year Ended December 31, 2024 2023 2022 Medicare 98.3 % 97.1 % 98.8 % Managed care 1.7 % 2.5 % 0.7 % Medicaid — % 0.4 % 0.5 % Total 100.0 % 100.0 % 100.0 % Additional information regarding our Hospice segment’s operating results for the years ended December 31, 2024, 2023, and 2022 is as follows: Year Ended December 31, Percentage Change (in millions, except percentages) 2024 2023 2022 2024 vs. 2023 2023 vs. 2022 Hospice net service revenue $ 210.0 $ 196.2 $ 194.0 7.0 % 1.1 % Cost of service, excluding depreciation and amortization 102.6 96.6 90.1 6.2 % 7.2 % Gross margin, excluding depreciation and amortization 107.4 99.6 103.9 7.8 % (4.1) % General and administrative expenses 65.5 63.4 65.2 3.3 % (2.8) % Equity earnings and noncontrolling interests 0.4 0.1 0.3 300.0 % (66.7) % Hospice Segment Adjusted EBITDA (1) $ 41.5 $ 36.1 $ 38.4 15.0 % (6.0) % Year Ended December 31, Percentage Change (actual amounts) 2024 2023 2022 2024 vs. 2023 2023 vs. 2022 Total: Admissions 12,025 11,713 11,978 2.7% (2.2)% Same-store total admissions growth 0.5% (6.3)% Patient days 1,304,878 1,256,081 1,284,386 3.9% (2.2)% Discharged average length of stay 105 108 108 (2.8)% —% Average daily census 3,565 3,441 3,519 3.6% (2.2)% Revenue per patient day $ 160.9 $ 156.2 $ 151.0 3.0% 3.4% Cost per patient day $ 78.6 $ 76.9 $ 70.2 2.2% 9.5% (1) Segment Adjusted EBITDA is presented in conformity with ASC 280, Segment Reporting , as a measure reported to management for purposes of making decisions on allocating resources and addressing the performance of our segments.
For additional information about our business and reportable segments, see Item 1, “ Business ,” Item 1A, “ Risk Factors ,” “— Segment Results of Operations ,” and Note 14, Segment Reporting , to the accompanying consolidated financial statements in this Annual Report.
For additional information about our business and reportable segments, see Item 1, “ Business ,” Item 1A, “ Risk Factors ,” “— Segment Results of Operations ,” and Note 14, Segment Reporting , to the accompanying consolidated financial statements in this Annual Report. 33 Table of Contents Factors Affecting Our Performance There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth.
We believe the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results, as they require our most difficult, subjective, or complex judgments resulting from the need to make estimates about the effect of matters that are inherently uncertain.
We believe the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results, as they require our most difficult, subjective, or complex judgments resulting from the need to make estimates about the effect of matters that are inherently uncertain. 44 Table of Contents Revenue Recognition We recognize Net service revenue in the reporting period in which we perform the service based on our best estimate of the transaction price for the type of service provided to the patient.
Because we derive a substantial portion of our Net service revenue from the Medicare program, our results of operations are heavily impacted by changes in Medicare reimbursement rates. Medicare reimbursement rates are subject to change annually, with the potential for more sweeping changes from time to time as a result of Congressional or state legislation.
Medicare reimbursement rates are subject to change annually, with the potential for more sweeping changes from time to time as a result of Congressional or state legislation.
In determining the fair value of assets acquired and liabilities assumed in a business combination, we primarily use the income and multi-period excess earnings approaches to estimate the value of our most significant acquired intangible assets.
During the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. 47 Table of Contents In determining the fair value of assets acquired and liabilities assumed in a business combination, we primarily use the income and multi-period excess earnings approaches to estimate the value of our most significant acquired intangible assets.
Expenses as a % of Net Service Revenue For the Year Ended December 31, 2023 2022 2021 Cost of service, excluding depreciation and amortization 49.2% 46.4% 43.2% General and administrative expenses 32.3% 33.6% 29.9% 45 Net service revenue The increase in hospice Net service revenue for the year ended December 31, 2023 as compared to the year ended December 31, 2022 primarily resulted from an increase in revenue per patient day.
Expenses as a % of Net Service Revenue Year Ended December 31, 2024 2023 2022 Cost of service, excluding depreciation and amortization 48.9% 49.2% 46.4% General and administrative expenses 31.2% 32.3% 33.6% 42 Table of Contents Net Service Revenue.
We based our fair value estimates on assumptions management believed to be reasonable but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates. Income Taxes We provide for income taxes using the asset and liability method.
We based our fair value estimates 46 Table of Contents on assumptions management believed to be reasonable but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates. See Note 7, Goodwill and Other Intangible Assets, Net , to the accompanying consolidated financial statements for additional information.
See also Note 1, Summary of Significant Accounting Policies —Basis of Presentation and Consolidation , and Note 11, Income Taxes , to the accompanying consolidated financial statements, and “ —Critical Accounting Estimates .” Adjusted EBITDA Adjusted EBITDA is a non-GAAP measure of our financial performance.
The difference in the effective rate is primarily due to a valuation allowance recorded against a portion of our deferred tax assets in 2024. See Note 11, Income Taxes , to the accompanying consolidated financial statements, and “ —Critical Accounting Estimates .” Adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure of our financial performance.
However, we continually review the amounts actually collected in subsequent periods in order to determine the amounts by which our estimates differed.
However, we continually review the amounts actually collected in subsequent periods in order to determine the amounts by which our estimates differed. The collection of outstanding receivables from third-party payers and patients is our primary source of cash and is critical to our operating performance.
For the Year Ended December 31, 2023 % of Consolidated Revenue 2022 % of Consolidated Revenue 2021 % of Consolidated Revenue (In Millions) Home health segment net service revenue $ 850.1 81.2 % $ 877.1 81.9 % $ 897.3 81.1 % Hospice segment net service revenue 196.2 18.8 % 194.0 18.1 % 209.3 18.9 % Consolidated net service revenue $ 1,046.3 100.0 % $ 1,071.1 100.0 % $ 1,106.6 100.0 % 42 For the year ended December 31, 2023, our Net service revenue decreased 2.3% over 2022 due to the continued shift to more non-episodic patients in home health and the resumption of sequestration.
Year Ended December 31, 2024 2023 2022 (in millions, except percentages) $ Amount % of Consolidated Revenue $ Amount % of Consolidated Revenue $ Amount % of Consolidated Revenue Home Health segment net service revenue $ 824.8 79.7 % $ 850.1 81.2 % $ 877.1 81.9 % Hospice segment net service revenue 210.0 20.3 % 196.2 18.8 % 194.0 18.1 % Consolidated net service revenue $ 1,034.8 100.0 % $ 1,046.3 100.0 % $ 1,071.1 100.0 % For the year ended December 31, 2024, our Consolidated net service revenue decreased 1.1% compared to the prior year due to a decrease in Home Health segment revenues of 3.0% with average daily census in Home Health lower by 2.1% and unit revenue per patient day lower by 1.3% primarily related to the continued unfavorable mix shift to more non‑Medicare patients in the Home Health segment.
Impairment of Goodwill Impairment of goodwill for the year ended December 31, 2023 resulted from an impairment charge to reduce the carrying value of our hospice reporting unit to its fair value.
For the year ended December 31, 2024, Depreciation and amortization increased compared to the prior year due to our investments in technology and fleet vehicles in 2024. Impairment of Goodwill. For the year ended December 31, 2024, Impairment of goodwill resulted from impairment charges to reduce the carrying value of our Home Health reporting unit to its fair value.
Segment Adjusted EBITDA The decrease in hospice Segment Adjusted EBITDA for the year ended December 31, 2023 as compared to the year ended December 31, 2022 primarily resulted from an increase in Cost of service , excluding depreciation and amortization .
Segment Adjusted EBITDA. The increase in Hospice Segment Adjusted EBITDA of 15.0% for the year ended December 31, 2024 as compared to the prior year primarily resulted from the increase in Net service revenue of 7.0% discussed above with Cost of service, excluding depreciation and amortization, higher by 6.2% to support revenue growth, partially offset by improved clinical staff productivity.
Contractual Obligations Our consolidated contractual obligations as of December 31, 2023 are as follows (in millions): Total Current Long Term Long-term debt obligations: Long-term debt, excluding revolving credit facility and finance lease obligations (a) $ 367.1 $ 20.0 $ 347.1 Revolving credit facility 180.0 — 180.0 Interest on long-term debt (b) 152.3 43.5 108.8 Finance lease obligations (a) 6.0 2.7 3.3 Operating lease obligations (c) 71.2 15.0 56.2 Purchase obligations (d) 7.4 5.6 1.8 Total $ 784.0 $ 86.8 $ 697.2 (a) We lease automobiles for our clinicians under finance leases.
The increase in Net cash used in financing activities for the year ended December 31, 2024 as compared to the prior year resulted primarily from an increase in net repayments of debt in 2024. 43 Table of Contents Contractual Obligations Our consolidated contractual obligations as of December 31, 2024 are as follows (in millions): Total Current Long-Term Long-term debt obligations: Long-term debt, excluding revolving credit facility and finance lease obligations (1) $ 348.0 $ 20.0 $ 328.0 Revolving credit facility 160.0 — 160.0 Interest on long-term debt (2) 105.9 35.3 70.6 Finance lease obligations (1) 8.1 3.0 5.1 Operating lease obligations (3) 66.1 15.4 50.7 Purchase obligations (4) 22.8 18.3 4.5 Total $ 710.9 $ 92.0 $ 618.9 (1) We lease automobiles under finance leases for our clinicians.
Home Health During the years ended December 31, 2023, 2022, and 2021, our home health segment derived its Net service revenue from the following payor sources: For the Year Ended December 31, 2023 2022 2021 Medicare 65.6 % 73.8 % 78.2 % Medicare Advantage 23.4 % 17.3 % 13.1 % Managed care 9.5 % 7.3 % 6.9 % Medicaid 1.4 % 1.4 % 1.6 % Other 0.1 % 0.2 % 0.2 % Total 100.0 % 100.0 % 100.0 % The decline in Medicare revenue as a percentage of our home health Net service revenue and corresponding increase in Medicare Advantage revenue is primarily the result of continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries.
Home Health During the years ended December 31, 2024, 2023, and 2022, our Home Health segment derived its Net service revenue from the following payer sources: Year Ended December 31, 2024 2023 2022 Medicare 58.8 % 65.6 % 73.8 % Medicare Advantage 28.8 % 23.4 % 17.3 % Managed Care 11.1 % 9.5 % 7.3 % Medicaid 1.1 % 1.4 % 1.4 % Other 0.2 % 0.1 % 0.2 % Total 100.0 % 100.0 % 100.0 % The decline in Medicare revenue as a percentage of our Home Health Net service revenue and corresponding increase in Medicare Advantage revenue is primarily the result of continued national enrollment increases in Medicare Advantage plans by Medicare beneficiaries. 39 Table of Contents Additional information regarding our Home Health segment’s operating results for the years ended December 31, 2024, 2023, and 2022 is as follows: Year Ended December 31, Percentage Change (in millions, except percentages) 2024 2023 2022 2024 vs. 2023 2023 vs. 2022 Net service revenue: Medicare $ 484.6 $ 557.4 $ 647.7 (13.1) % (13.9) % Non-Medicare 331.2 283.0 218.3 17.0 % 29.6 % Private duty (1) 9.0 9.7 11.1 (7.2) % (12.6) % Home Health net service revenue 824.8 850.1 877.1 (3.0) % (3.1) % Cost of service, excluding depreciation and amortization 428.2 439.0 435.5 (2.5) % 0.8 % Gross margin, excluding depreciation and amortization 396.6 411.1 441.6 (3.5) % (6.9) % General and administrative expenses 235.4 240.6 238.5 (2.2) % 0.9 % Other income — (0.2) (0.9) (100.0) % (77.8) % Equity earnings and noncontrolling interests 1.8 1.4 1.8 28.6 % (22.2) % Home Health Segment Adjusted EBITDA (2) $ 159.4 $ 169.3 $ 202.2 (5.8) % (16.3) % (1) Private duty represents long-term comprehensive hourly nursing medical care.
Factors Affecting Our Performance There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth. These factors include: Pricing Generally, the pricing we receive for our services is based on reimbursement rates from payors.
These factors include: Pricing Generally, the pricing we receive for our services is based on reimbursement rates from payers. Because we derive a substantial portion of our Net service revenue from the Medicare program, our results of operations are heavily impacted by changes in Medicare reimbursement rates.
See “— Liquidity and Capital Resources .” Income Tax (Benefit) Expense Our effective tax rate in 2023 was 12.6% compared to an effective tax rate of (50.2)% in 2022. In 2023, the effective tax rate was impacted by the goodwill impairment in our hospice reporting unit, a significant portion of which was a permanent book-tax difference.
For the year ended December 31, 2024, Interest expense and amortization of debt discounts and fees remained relatively flat compared to the prior year. See “— Liquidity and Capital Resources .” (Benefit From) Provision For Income Taxes. Our effective tax rate in 2024 was 2.5% compared to an effective tax rate of 12.6% in 2023.
A high degree of judgment is required to determine the extent a valuation allowance should be provided against deferred tax assets. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets, considering all available evidence, both positive and negative.
A high degree of judgment can be required to determine the extent a valuation allowance should be provided against deferred tax assets. Due to the pretax losses we have generated in recent years, we recorded a valuation allowance of $14.1 million in 2024.
Cost of service , excluding depreciation and amortization increased for the year ended December 31, 2023 as compared to December 31, 2022 due to an increase in labor costs, primarily as a result of annual merit and market increases and implementation of the case management staffing model in hospice, partially offset by a reduction in contract labor.
For the year ended December 31, 2024, General and administrative expenses decreased compared to the prior year primarily due to cost savings initiatives, lower benefit related expenses, and incentive compensation, partially offset by annual merit increases in the fourth quarter of 2023 and 2024. Depreciation and Amortization.
Expenses as a % of Net Service Revenue For the Year Ended December 31, 2023 2022 2021 Cost of service, excluding depreciation and amortization 51.6 % 49.7 % 47.2 % General and administrative expenses 28.3 % 27.2 % 27.2 % Net Service Revenue The decrease in home health Net service revenue for the year ended December 31, 2023 as compared to the year ended December 31, 2022 primarily was due to the continued shift to more non-episodic patients in home health and the resumption of sequestration.
The decrease in Home Health Net service revenue for the year ended December 31, 2024 as compared to the prior year of 3.0% is due to average daily census in Home Health being lower by 2.1% and unit revenue per patient day being lower by 1.3% primarily related to the continued unfavorable mix shift to more non-Medicare patients in the Home Health segment.
The increase in revenue per patient day for the year ended December 31, 2023 primarily was due to increased Medicare reimbursement rates and changes in our estimated recoverability of Net service revenue , partially offset by the resumption of sequestration.
The increase in Hospice Net service revenue for the year ended December 31, 2024 as compared to the prior year of 7.0% was due to improved unit revenue per patient day of 3.0% on improved Medicare reimbursement rates and growth in average daily census of 3.6% on strong admissions growth as we continue to see the benefits of the maturing case management model.